Rucaparib Monotherapy in Patients With Pancreatic Cancer and a Known Deleterious BRCA Mutation

PURPOSE: Pancreatic cancer has a poor prognosis and limited treatment options. Approximately 9% of pancreatic cancers harbor a germline or somatic BRCA1 or BRCA2 (BRCA1/2) mutation. Because poly (ADP-ribose) polymerase inhibitors have significant activity in BRCA1/2-mutant ovarian and breast cancers...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:JCO Precis Oncol
Glavni autori: Shroff, Rachna T., Hendifar, Andrew, McWilliams, Robert R., Geva, Ravit, Epelbaum, Ron, Rolfe, Lindsey, Goble, Sandra, Lin, Kevin K., Biankin, Andrew V., Giordano, Heidi, Vonderheide, Robert H., Domchek, Susan M.
Format: Artigo
Jezik:Inglês
Izdano: American Society of Clinical Oncology 2018
Teme:
Original Report
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6057747/
https://ncbi.nlm.nih.gov/pubmed/30051098
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/PO.17.00316
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items